COMMUNIQUÉS West-GlobeNewswire

Bright Peak Therapeutics Presents New Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
09/04/2024
BPT567, a first-in-class PD1-IL18 immunoconjugate designed to enable cis-signaling and preferentially activate intratumoral PD1+IL18R+ effector T cells induces potent preclinical antitumor activity SAN DIEGO and BASEL, [...]
AssureCare Celebrates Parth Shah's Recognition as a Leader in Healthcare Innovation
09/04/2024
CINCINNATI, April 09, 2024 (GLOBE NEWSWIRE) -- AssureCare , a leading healthcare technology company, proudly announces the recognition of Parth Shah, Vice President of Product, in HealthCare Innovation's esteemed 40 [...]
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
09/04/2024
Presented new case studies demonstrating clinical responses in two patients with B cell malignancies, chronic lymphocytic leukemia (CLL) and primary central nervous system lymphoma (PCNSL), each with central nervous [...]
Inc.’s 2024 Female Founders list highlights why female founders are always a good bet
09/04/2024
adyn founder, Elizabeth Ruzzo, named to the list SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Inc. today announced its seventh annual Female Founders list, honoring a bold group of 250 women whose innovations and ideas [...]
EUROAPI streamlines its Executive Committee to improve focus and efficiency
09/04/2024
Press Release Paris – April 9, 2024 – EUROAPI today announces a streamlining of its Executive Committee around operational functions in order to improve focus and efficiency. This organizational adjustment is part of [...]
EUROAPI resserre son Comité exécutif afin de se recentrer et de gagner en efficacité
09/04/2024
Communiqué de presse Paris – Le 9 avril 2024 – EUROAPI annonce aujourd’hui un resserrement de son Comité exécutif autour des fonctions opérationnelles, afin de se recentrer et de gagner en efficacité. Cet ajustement [...]
Current constipation medications don't provide relief for some patients with Chronic Idiopathic Constipation, per Gastroenterologist survey
09/04/2024
Vibrant Gastro’s non-pharmaceutical vibrating capsule technology offers alternative for patients to regain control over their lives BOSTON, April 09, 2024 (GLOBE NEWSWIRE) -- Millions of Americans currently receiving [...]
Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
09/04/2024
MDNA113 is targeted to the tumor site where it is activated to simultaneously deliver two immunotherapies, an IL-2 superkine and anti-PD1 antibody, to the same cancer fighting immune cells in the tumor micro-environment [...]
Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024
09/04/2024
Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients. Encouraging VAXINIA efficacy, including a complete response (CR) and two partial [...]
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103
09/04/2024
Non-Clinical Poster Data Support the Use of Dual Antigen Approach to Enhance Anti-Tumor Activity NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company [...]
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
09/04/2024
- Preclinical data presented at AACR demonstrate that combining IMM-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor growth inhibition than either [...]
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
09/04/2024
- Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status - Confirmed ORR of 17.4% in subset of patients with PD-L1+ disease - Confirmed ORR of 22.2% in subset of patients with [...]
Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
09/04/2024
Major Histocompatibility Complex Class I (MHC-I) negative tumors are refractory to immune-oncology therapies, including resistance to checkpoint blockers, due to the loss of the fundamental recognition of the tumor by [...]
Monthly information related to total number of voting rights and shares composing the share capital – March 29, 2024
09/04/2024
Article 223-16 of general regulation of French Autorité des Marchés Financiers Listing market: Euronext Paris (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM) Website : www.phaxiam.com Date Total of shares [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 29 mars 2024
09/04/2024
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 29 mars 2024 Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers Place de cotation : [...]
Nicox: 2024 Ordinary and Extraordinary Shareholder Meeting
09/04/2024
Press Release Nicox: 2024 Ordinary and Extraordinary Shareholder Meeting April 9, 2024 – release at 17:30 CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, ALCOX), an international ophthalmology [...]
Nicox : Assemblée Générale Ordinaire et Extraordinaire 2024
09/04/2024
Communiqué de presse Nicox : Assemblée Générale Ordinaire et Extraordinaire 2024 9 avril 2024 – diffusion à 17h30 Sophia Antipolis, France Nicox SA (Euronext Paris : FR0013018124, ALCOX, éligible PEA-PME), société [...]
QIAGEN N.V. to release results for Q1 2024 and hold webcast
09/04/2024
Venlo, The Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2024. Press release date / time: Monday, April [...]
Optimi Health Signs Psilocybin Supply Agreement With New Zealand-Based Mātai Medical Research Institute
09/04/2024
VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in [...]

Pages